Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab

  • Technology appraisal guidance
  • TA357
  • Published: 
  • Last updated: 

History

Documents created during the development process.

Invitation to participate

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final appraisal determination

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: scope consultation comments table

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final scope

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: equality impact assessment

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final matrix